Exact Sciences Q4 EPS $(0.27) Beats $(0.46) Estimate, Sales $646.88M Beat $637.22M Estimate
Portfolio Pulse from Happy Mohamed
Exact Sciences (NASDAQ:EXAS) reported Q4 earnings with losses of $(0.27) per share, surpassing the $(0.46) estimate, and sales of $646.88M, exceeding the $637.22M estimate. This represents a significant improvement over the previous year.
February 21, 2024 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exact Sciences reported better-than-expected Q4 earnings and sales, indicating strong year-over-year growth.
The significant beat on both earnings and sales estimates, coupled with the substantial year-over-year growth, suggests a positive outlook for Exact Sciences. This performance could lead to increased investor confidence and a potential uptick in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100